213 related articles for article (PubMed ID: 32028983)
1. Systematic functional identification of cancer multi-drug resistance genes.
Lau MT; Ghazanfar S; Parkin A; Chou A; Rouaen JR; Littleboy JB; Nessem D; Khuong TM; Nevoltris D; Schofield P; Langley D; Christ D; Yang J; Pajic M; Neely GG
Genome Biol; 2020 Feb; 21(1):27. PubMed ID: 32028983
[TBL] [Abstract][Full Text] [Related]
2. New tools for old drugs: Functional genetic screens to optimize current chemotherapy.
Gerhards NM; Rottenberg S
Drug Resist Updat; 2018 Jan; 36():30-46. PubMed ID: 29499836
[TBL] [Abstract][Full Text] [Related]
3. Targeted CRISPR activation and knockout screenings identify novel doxorubicin transporters.
Li Y; Tan M; Sun S; Stea E; Pang B
Cell Oncol (Dordr); 2023 Dec; 46(6):1807-1820. PubMed ID: 37523060
[TBL] [Abstract][Full Text] [Related]
4. Chemical genomics with pyrvinium identifies C1orf115 as a regulator of drug efflux.
Masud SN; Chandrashekhar M; Aregger M; Tan G; Zhang X; Mero P; Pirman DA; Zaslaver O; Smolen GA; Lin ZY; Wong CJ; Boone C; Gingras AC; Montenegro-Burke JR; Moffat J
Nat Chem Biol; 2022 Dec; 18(12):1370-1379. PubMed ID: 35970996
[TBL] [Abstract][Full Text] [Related]
5. Pooled CRISPR screening in pancreatic cancer cells implicates co-repressor complexes as a cause of multiple drug resistance via regulation of epithelial-to-mesenchymal transition.
Ramaker RC; Hardigan AA; Gordon ER; Wright CA; Myers RM; Cooper SJ
BMC Cancer; 2021 May; 21(1):632. PubMed ID: 34049503
[TBL] [Abstract][Full Text] [Related]
6. Genomics and cancer drug resistance.
Rodrigues AS; Dinis J; Gromicho M; Martins C; Laires A; Rueff J
Curr Pharm Biotechnol; 2012 Apr; 13(5):651-73. PubMed ID: 22122479
[TBL] [Abstract][Full Text] [Related]
7. CRISPR/Cas9 for overcoming drug resistance in solid tumors.
Saber A; Liu B; Ebrahimi P; Haisma HJ
Daru; 2020 Jun; 28(1):295-304. PubMed ID: 30666557
[TBL] [Abstract][Full Text] [Related]
8. Genome-wide CRISPR/Cas9 knockout screening uncovers a novel inflammatory pathway critical for resistance to arginine-deprivation therapy.
Chu CY; Lee YC; Hsieh CH; Yeh CT; Chao TY; Chen PH; Lin IH; Hsieh TH; Shih JW; Cheng CH; Chang CC; Lin PS; Huang YL; Chen TM; Yen Y; Ann DK; Kung HJ
Theranostics; 2021; 11(8):3624-3641. PubMed ID: 33664852
[TBL] [Abstract][Full Text] [Related]
9. Dual genome-wide CRISPR knockout and CRISPR activation screens identify mechanisms that regulate the resistance to multiple ATR inhibitors.
Schleicher EM; Dhoonmoon A; Jackson LM; Clements KE; Stump CL; Nicolae CM; Moldovan GL
PLoS Genet; 2020 Nov; 16(11):e1009176. PubMed ID: 33137164
[TBL] [Abstract][Full Text] [Related]
10. Targeting ABCB1 (MDR1) in multi-drug resistant osteosarcoma cells using the CRISPR-Cas9 system to reverse drug resistance.
Liu T; Li Z; Zhang Q; De Amorim Bernstein K; Lozano-Calderon S; Choy E; Hornicek FJ; Duan Z
Oncotarget; 2016 Dec; 7(50):83502-83513. PubMed ID: 27835872
[TBL] [Abstract][Full Text] [Related]
11. ZEB1 transcriptionally regulated carbonic anhydrase 9 mediates the chemoresistance of tongue cancer via maintaining intracellular pH.
Zheng G; Peng C; Jia X; Gu Y; Zhang Z; Deng Y; Wang C; Li N; Yin J; Liu X; Lu M; Tang H; He Z
Mol Cancer; 2015 Apr; 14():84. PubMed ID: 25890268
[TBL] [Abstract][Full Text] [Related]
12. RRM2 and CDC6 are novel effectors of XBP1-mediated endocrine resistance and predictive markers of tamoxifen sensitivity.
Barua D; Sultana A; Islam MN; Cox F; Gupta A; Gupta S
BMC Cancer; 2023 Mar; 23(1):288. PubMed ID: 36997866
[TBL] [Abstract][Full Text] [Related]
13. CRISPR/Cas9 nanoeditor of double knockout large fragments of E6 and E7 oncogenes for reversing drugs resistance in cervical cancer.
Li X; Guo M; Hou B; Zheng B; Wang Z; Huang M; Xu Y; Chang J; Wang T
J Nanobiotechnology; 2021 Aug; 19(1):231. PubMed ID: 34353334
[TBL] [Abstract][Full Text] [Related]
14. Inside the biochemical pathways of thymidylate synthase perturbed by anticancer drugs: Novel strategies to overcome cancer chemoresistance.
Taddia L; D'Arca D; Ferrari S; Marraccini C; Severi L; Ponterini G; Assaraf YG; Marverti G; Costi MP
Drug Resist Updat; 2015 Nov; 23():20-54. PubMed ID: 26690339
[TBL] [Abstract][Full Text] [Related]
15. Identification of Personalized Chemoresistance Genes in Subtypes of Basal-Like Breast Cancer Based on Functional Differences Using Pathway Analysis.
Wu T; Wang X; Li J; Song X; Wang Y; Wang Y; Zhang L; Li Z; Tian J
PLoS One; 2015; 10(6):e0131183. PubMed ID: 26126114
[TBL] [Abstract][Full Text] [Related]
16. CRISPR screens uncover protective effect of PSTK as a regulator of chemotherapy-induced ferroptosis in hepatocellular carcinoma.
Chen Y; Li L; Lan J; Cui Y; Rao X; Zhao J; Xing T; Ju G; Song G; Lou J; Liang J
Mol Cancer; 2022 Jan; 21(1):11. PubMed ID: 34983546
[TBL] [Abstract][Full Text] [Related]
17. Role of the Drug Transporter ABCC3 in Breast Cancer Chemoresistance.
Balaji SA; Udupa N; Chamallamudi MR; Gupta V; Rangarajan A
PLoS One; 2016; 11(5):e0155013. PubMed ID: 27171227
[TBL] [Abstract][Full Text] [Related]
18. A meta-analysis approach for characterizing pan-cancer mechanisms of drug sensitivity in cell lines.
Wang K; Shrestha R; Wyatt AW; Reddy A; Lehár J; Wang Y; Lapuk A; Collins CC
PLoS One; 2014; 9(7):e103050. PubMed ID: 25036042
[TBL] [Abstract][Full Text] [Related]
19. Genome-wide CRISPR screens reveal genetic mediators of cereblon modulator toxicity in primary effusion lymphoma.
Patil A; Manzano M; Gottwein E
Blood Adv; 2019 Jul; 3(14):2105-2117. PubMed ID: 31300418
[TBL] [Abstract][Full Text] [Related]
20. Functional Genomics Approaches to Elucidate Vulnerabilities of Intrinsic and Acquired Chemotherapy Resistance.
Cetin R; Quandt E; Kaulich M
Cells; 2021 Jan; 10(2):. PubMed ID: 33525637
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
